Samrat Pharma

Which are the latest news on Samrat Pharma?

Why is Samrat Pharmachem Ltd falling/rising?

As of 05-Sep, the stock price of Samrat Pharmachem Ltd is at 231.50, reflecting a decline of 2.26%. This drop is due to poor recent performance, reduced investor interest, and the stock's inability to maintain momentum compared to its sector and the broader market.

As of 05-Sep, the stock price of Samrat Pharmachem Ltd is falling, currently at 231.50, which reflects a decrease of 5.35 or 2.26%. This decline can be attributed to several factors. Over the past week, the stock has underperformed, showing a loss of 3.92%, while the benchmark Sensex has only decreased by 0.97%. Additionally, the stock has experienced a significant drop of 6.24% over the past month, compared to a 2.44% decline in the Sensex.<BR><BR>Today's performance indicates that the stock opened with a loss of 2.64% and reached an intraday low of Rs 230, marking a decrease of 2.89%. The stock's performance today has also underperformed its sector by 1.87%. Furthermore, there is a notable decline in investor participation, with delivery volume falling by 7.89% against the 5-day average. Although the stock is trading above its 100-day and 200-day moving averages, it is below its 5-day, 20-day, and 50-day moving averages, suggesting a short-term weakness.<BR><BR>Overall, the combination of poor recent performance, reduced investor interest, and the stock's inability to maintain momentum against both its sector and the broader market contributes to the ongoing decline in its price.

Who are in the management team of Samrat Pharma?

The management team of Samrat Pharma includes Lalit Mehta (Chairman & Managing Director), Rajesh Mehta (Director & CFO), Mahendra Pipalia, Samir Kothary, and Renu P Dharod (all Independent Directors), Megh Mehta (Executive Director), and Nishant Kankaria (Company Secretary & Compliance Officer).

The management team of Samrat Pharma includes the following individuals:<BR><BR>1. **Lalit Mehta** - Chairman & Managing Director<BR>2. **Rajesh Mehta** - Director & CFO<BR>3. **Mahendra Pipalia** - Independent Director<BR>4. **Samir Kothary** - Independent Director<BR>5. **Renu P Dharod** - Independent Director<BR>6. **Megh Mehta** - Executive Director<BR>7. **Nishant Kankaria** - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

What does Samrat Pharma do?

Samrat Pharmachem Ltd manufactures and sells chemicals in the Pharmaceuticals & Biotechnology industry, operating as a Micro Cap company. As of June 2026, it reported net sales of 80 Cr and a net profit of 1 Cr.

Overview:<BR>Samrat Pharmachem Ltd is engaged in the manufacturing and selling of chemicals within the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated on June 16, 1992. In the fiscal year 2003-04, it established a 100% subsidiary named Samrat Remedies Limited, which focuses on the manufacturing of pharmaceutical bulk drugs and chemicals. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 80 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 74 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.42%<BR>- Debt-Equity: 0.06<BR>- Return on Equity: -3.24%<BR>- Price to Book: 1.09<BR><BR>Contact Details:<BR>- Address: Plot No A2/3445, GIDC Phase IV Ankleshwar Gujarat : 393002<BR>- Tel: 91-2646-220774<BR>- Email: samrat@bom4.vsnl.net.in<BR>- Website: http://www.samratpharmachem.com

Who are the peers of the Samrat Pharma?

Samrat Pharma's peers include Asston Pharma, Mercury Labs, Amwill Health, Sunil Healthcare, Vineet Laborator, Source Natural, Bharat Immunolog, Onyx Biotec, Zenith Drugs, and Ajooni Biotech. In terms of management risk, growth, and capital structure, Amwill Health stands out positively, while Vineet Laborator has the highest 1-year return at 39.69%, and Samrat Pharma's return is -25.91%.

Peers: The peers of Samrat Pharma are Asston Pharmaceu, Mercury Labs, Amwill Health, Sunil Healthcare, Vineet Laborator, Source Natural, Bharat Immunolog, Onyx Biotec, Zenith Drugs, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill Health and Source Natural, while Average management risk is found at Asston Pharmaceu, Mercury Labs, Samrat Pharma, and Onyx Biotec. Below Average management risk is present at Sunil Healthcare, Vineet Laborator, Bharat Immunolog, and Zenith Drugs, and the rest. Growth is Excellent at Amwill Health, Good at Sunil Healthcare and Ajooni Biotech, Average at Mercury Labs and Samrat Pharma, and Below Average at Asston Pharmaceu, Vineet Laborator, Source Natural, Bharat Immunolog, Onyx Biotec, and Zenith Drugs. Capital Structure is Excellent at Amwill Health and Samrat Pharma, Good at Source Natural and Ajooni Biotech, Average at Asston Pharmaceu, Mercury Labs, and Onyx Biotec, and Below Average at Sunil Healthcare, Vineet Laborator, Bharat Immunolog, and Zenith Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vineet Laborator at 39.69%, while the lowest is Bharat Immunolog at -27.90%. Samrat Pharma's 1-year return is -25.91%, which is higher than Bharat Immunolog's but lower than Vineet Laborator's. Additionally, the six-month return is negative for Mercury Labs, Bharat Immunolog, and Source Natural.

How big is Samrat Pharma?

As of 31st August, Samrat Pharmachem Ltd has a market capitalization of 74.00 Cr and reported Net Sales of 293.83 Cr, with a Net Profit loss of 2.21 Cr over the latest four quarters.

As of 31st August, Samrat Pharmachem Ltd has a market capitalization of 74.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 293.83 Cr. However, it experienced a loss of 2.21 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2026, where Shareholder's Funds amounted to 68.18 Cr and Total Assets were reported at 124.42 Cr.

Should I buy, sell or hold Samrat Pharmachem Ltd?

Are Samrat Pharmachem Ltd latest results good or bad?

Samrat Pharmachem Ltd's latest results are concerning, reporting a net loss of ₹2.04 crores in Q4 FY26, a 410% decline year-on-year, with negative operating margins and four consecutive quarters of losses, indicating severe operational distress.

The latest results for Samrat Pharmachem Ltd are concerning. In the fourth quarter of FY26, the company reported a net loss of ₹2.04 crores, which is a significant decline of 410% year-on-year. This marks the worst quarterly performance on record for the company. While revenue showed a slight increase of 0.80% year-on-year, reaching ₹71.77 crores, this growth is overshadowed by a catastrophic drop in profitability.<BR><BR>The operating margin turned negative at -1.73%, a stark contrast to the positive margins reported in previous years. Additionally, the profit before tax fell to negative ₹1.87 crores from negative ₹0.36 crores in the same quarter last year. The PAT margin also deteriorated sharply to -2.84% from -0.56% a year earlier.<BR><BR>Overall, the financial performance indicates severe operational distress, with four consecutive quarters of losses and a significant erosion of profitability. Given these results, it can be concluded that the latest performance of Samrat Pharmachem Ltd is quite bad, raising serious concerns about its future viability and operational stability.

Is Samrat Pharma overvalued or undervalued?

As of November 18, 2025, Samrat Pharma is considered overvalued with a PE Ratio of 53.48, significantly higher than its peers, and has experienced a poor year-to-date return of -29.33%, indicating a shift in market perception from very attractive to very expensive.

As of 18 November 2025, the valuation grade for Samrat Pharma has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 53.48, an EV to EBITDA of 18.52, and a Price to Book Value of 1.18, all of which suggest that the stock is priced at a premium compared to its earnings and assets.<BR><BR>In comparison to its peers, Samrat Pharma's PE Ratio is notably higher than Sun Pharma's 36.56 and significantly exceeds Cipla's more attractive valuation at 22.49. Additionally, while the PEG Ratio stands at 0.00, indicating no growth expectations priced in, other competitors like Divi's Lab show a PEG of 1.96, reflecting a more balanced valuation. The company's recent stock performance has been poor, with a year-to-date return of -29.33%, contrasting sharply with the Sensex's gain of 8.36%, further reinforcing the notion that Samrat Pharma is overvalued in the current market environment.

How has been the historical performance of Samrat Pharma?

Samrat Pharma's historical performance shows fluctuating financial metrics, with net sales rising from INR 137.45 crore in March 2020 to a peak of INR 310.65 crore in March 2023, followed by a decline and slight recovery. Key indicators like operating profit and profit after tax also experienced significant volatility during this period.

Answer:<BR>The historical performance of Samrat Pharma shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Samrat Pharma's net sales increased from INR 137.45 crore in March 2020 to INR 285.86 crore in March 2025, with a peak of INR 310.65 crore in March 2023. However, there was a decline in net sales from March 2023 to March 2024, followed by a slight recovery in March 2025. The total operating income mirrored this trend, reaching INR 310.65 crore in March 2023 before dropping to INR 281.58 crore in March 2024 and rebounding to INR 285.86 crore in March 2025. The operating profit (PBDIT) saw significant fluctuations, peaking at INR 24.89 crore in March 2022, then dropping to INR 2.47 crore in March 2024, and recovering to INR 10.24 crore in March 2025. Profit after tax also exhibited volatility, with a high of INR 16.63 crore in March 2023, declining to INR 2.16 crore in March 2024, and then increasing to INR 7.11 crore in March 2025. The company's total assets grew from INR 58.35 crore in March 2020 to INR 121.49 crore in March 2025, while total liabilities remained relatively stable, peaking at INR 121.74 crore in March 2024. Cash flow from operating activities was negative in March 2025 at INR -10 crore, contrasting with a positive cash flow of INR 9 crore in March 2024. Overall, Samrat Pharma's financial performance reflects a mix of growth and challenges over the years.

Who are the top shareholders of the Samrat Pharma?

The top shareholder of Samrat Pharma is Lalit Damodar Mehta, holding 13.97%. Individual investors collectively own 41.58%, while the highest public shareholder is Sangeetha S at 3.27%.

The top shareholders of Samrat Pharma include the promoters, with Lalit Damodar Mehta holding the largest share at 13.97%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sangeetha S, who owns 3.27%. Additionally, individual investors collectively hold 41.58% of the company's shares.

What is the technical trend for Samrat Pharma?

As of June 2, 2025, Samrat Pharma's technical outlook is mildly bearish, driven by bearish signals from moving averages and Bollinger Bands, despite some short-term strength indicated by the KST.

As of 2 June 2025, the technical trend for Samrat Pharma has changed from mildly bullish to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD is bearish, suggesting a divergence in time frames. The Bollinger Bands are bearish for both weekly and monthly periods, reinforcing the bearish outlook. Daily moving averages are also bearish, which adds to the negative sentiment. The KST shows a mildly bullish signal on the weekly but remains bullish on the monthly, indicating some strength in the short term. Dow Theory reflects a mildly bearish stance on the weekly, with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish signals from moving averages and Bollinger Bands.

When is the next results date for Samrat Pharma?

No Upcoming Board Meetings

Has Samrat Pharma declared dividend?

Yes, Samrat Pharma has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 19, 2024. The dividend yield is 0.28%, and while long-term returns have been positive, short-term performance has shown mixed results.

Samrat Pharma has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.28%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.34%, with a dividend return of 0%, resulting in a total return of -13.34%.<BR><BR>Over the past year, the price return was 2.78%, with a dividend return of 0.30%, leading to a total return of 3.08%.<BR><BR>In the 2-year period, the price return was -15.92%, while the dividend return was 0.47%, resulting in a total return of -15.45%.<BR><BR>For the 3-year period, the price return was -26.15%, with a dividend return of 0.80%, culminating in a total return of -25.35%.<BR><BR>In the last 4 years, the price return was 38.41%, with a dividend return of 1.26%, giving a total return of 39.67%.<BR><BR>Over the 5-year period, the price return was 363.67%, with a dividend return of 3.57%, resulting in a total return of 367.24%.<BR><BR>Overall, while Samrat Pharma has declared a dividend, the total returns over various periods show a mixed performance, with significant gains over the long term but negative returns in shorter periods. The dividend yield remains relatively low at 0.28%.